 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
1996 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laveille C. a), Le Coz F. b), Lerebours G. a), Resplandy G. a), and Jochemsen R. a) | Population Pharmacokinetics Of A New Bradycardic Agent In Healthy Male Volunteers: Influence Of Food And Time Of Administration | 7/18/2004 2:29:29 PM | poster |
Estimating Individual Pretreatment Levels Of A Pharmacologic Response Variable | 7/18/2004 2:05:54 PM | oral presentation | |
Optimal Design In Population Pharmacokinetics | 7/18/2004 2:35:03 PM | oral presentation | |
XPose - An S-Plus Based Model Building Aid For Population Analysis With Nonmem | 7/18/2004 2:34:32 PM | oral presentation | |
A Population PK/PD Model For The Anti-Parkinsonian Triple Therapy: Levodopa (Ld), Dopadecarboxylase (Ddc) Inhibitor And Catechol-O-Methyl Transferase (Comt) Inhibitor | 7/18/2004 2:33:52 PM | oral presentation | |
Individualized Drug Therapy And Population Modeling | 7/18/2004 2:32:55 PM | oral presentation | |
A Population Markov Model For Analyzing Dose History | 7/18/2004 2:31:50 PM | oral presentation | |
Prospective Evaluation Of A Formula To Predict Carboplatin Clearance In Children | 7/18/2004 2:36:20 PM | poster | |
Inter-Occasion Variation In The Bioavailability Of Benflumetol (An Anti Malarial Drug) | 7/18/2004 2:30:18 PM | oral presentation | |
Incorporation Of Population Pharmacokinetic Principles Into Drug Development | 7/18/2004 2:37:51 PM | poster | |
Presentation Of Population Analyses For Regulatory Submissions | 7/18/2004 2:28:41 PM | oral presentation | |
Assessment Of Covariate Relationships In The Analysis Of The Population Pharmacokinetics Of Tacrolimus. | 7/18/2004 2:27:53 PM | poster | |
Assessment Of Liver Blood Flow Using A Continuous Infusion Of A Drug With High Hepatic Clearance | 7/18/2004 2:27:09 PM | poster | |
M. Audran(1) , F. Bressolle (2), R. Gareau (3) and R. Gomeni (4) | A Population Pharmacodynamics Model Of Recombinant Human Erythropoietin In Athletes | 7/18/2004 2:26:30 PM | oral presentation |
Population Pharmacokinetics/ Pharmacodynamics Of Fluindione In Patients. | 7/18/2004 2:25:37 PM | poster | |
The Population Pharmacokinetics Of Ondansetron: A Covariate Analysis | 7/18/2004 2:09:02 PM | poster | |
D.Santos Buelga; M.E.Mendez*; M.J.Garcma; M.Pardo*; A.C.Falcao**; A.Dominguez-Gil. | Population Pharmacokinetics Of Tobramycin In Neonates | 7/18/2004 2:30:55 PM | poster |
MP2 (V 2.0) A Windows® Application For Population Pharmacokinetics | 7/18/2004 2:48:19 PM | poster | |
C.Pobel* - E.Chatelut+ - B.Tranchand x - J.N. Parola* - S.Demare* | Neural Network Prediction Of Dose And PP Parameters Values From A Population Approach Point Of View: Some Examples And Comments | 7/18/2004 3:00:22 PM | oral presentation |
Population Pharmacokinetics Of Proguanil In Patients With Acute P Falciparum Malaria After Combined Therapy With Atovaquone | 7/18/2004 2:59:24 PM | poster | |
The Relationship Of Phenytoin Concentrations To Gingival Hyperplasia | 7/18/2004 2:58:21 PM | poster | |
A Population Pharmacokinetic Study Of Ciprofloxacine Penetration In To Lung Tissue | 7/18/2004 2:57:40 PM | poster | |
Liarozole Population Pharmacokinetics At The Steady State | 7/18/2004 2:56:47 PM | poster | |
T Bouillon MD, D Kietzmann MD*, I Meineke PhD**, R Port MD§, A Hoeft MD | Pharmacokinetics Of Piritramide In Patients Undergoing Elective Surgery | 7/18/2004 2:56:19 PM | poster |
Experiences With CYP-2D6 Polymorphism In Clinical Drug Development | 7/18/2004 2:35:43 PM | poster | |
Marie Gårdmark, Mats O Karlsson and Margareta Hammarlund-Udenaes | A Pharmacokinetic Model For Morphine Incorporating Acute Tolerance And M3G Interactions | 7/18/2004 2:54:29 PM | poster |
Comparison Of ED, EID, API And Bayesian-API Criteria For The Robust Optimisation Of Sampling Times In Pharmacokinetics. | 7/18/2004 3:00:54 PM | oral presentation | |
VISUAL-NM (Version 1.0) | 7/18/2004 2:47:47 PM | software demonstration | |
Probability Statements About Predicted Kinetic/Dynamic Profiles In Population Analyses | 7/18/2004 2:46:57 PM | poster | |
POPKAN Demonstration | 7/18/2004 2:40:07 PM | software demonstration | |
A Preview of NONMEM Version V | 7/18/2004 2:39:37 PM | oral presentation | |
Simulating PK/PD Trials | 7/18/2004 2:39:05 PM | oral presentation | |
Willi Weber, Lutz Harnisch, Christian Rokitta, Jonathan Collins, H.-Juergen Roethig | Leflunomide Populationpharmacokinetics And Its Interaction With Activated Charcoal/Cholestyramine | 7/18/2004 2:38:40 PM | oral presentation |
Population Pharmacokinetics Of Valsartan | 7/18/2004 2:55:33 PM | poster |
